Brokerages Set Agenus Inc. (NASDAQ:AGEN) PT at $10.00

Shares of Agenus Inc. (NASDAQ:AGEN) have received a consensus rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research firms have recently weighed in on AGEN. HC Wainwright dropped their price objective on shares of Agenus from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, November 12th. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, B. Riley reduced their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its position in Agenus by 295.3% in the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 20,777 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after acquiring an additional 32,016 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in Agenus in the third quarter worth about $55,000. State Street Corp raised its holdings in Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the last quarter. Finally, Point72 DIFC Ltd raised its holdings in Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 11,542 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Up 16.8 %

Shares of Agenus stock opened at $3.34 on Thursday. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The stock has a market capitalization of $78.36 million, a P/E ratio of -0.30 and a beta of 1.39. The company has a 50-day simple moving average of $4.41 and a 200 day simple moving average of $8.33.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.